Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,759

Stocks News & Analysis

stocks

Impact on ASX REIT from David Jones collapse

Store closures could hit landlords.
stocks

This cheap dividend share might be overlooked

Short term pain, long term potential.
stocks

Why Morningstar thinks Anthropic is worth $1.7 trillion

A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,267.80104.401.14%
CAC 408,233.3094.301.16%
DAX 4026,267.19446.831.73%
Dow JONES (US)52,389.751,104.022.15%
FTSE 10010,782.87108.931.02%
HKSE24,540.8191.860.38%
NASDAQ25,253.14673.712.74%
Nikkei 22560,459.581,684.082.87%
NZX 50 Index14,167.41193.791.39%
S&P 5007,549.94173.082.35%
S&P/ASX 2009,129.0099.301.10%
SSE Composite Index3,663.722.930.08%

Market Movers